[Federal Register Volume 85, Number 142 (Thursday, July 23, 2020)] [Notices] [Page 44537] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 2020-15932] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Agency for Healthcare Research and Quality Notice of Meeting AGENCY: Agency for Healthcare Research and Quality, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The Agency for Healthcare Research and Quality (AHRQ) announces a Special Emphasis Panel (SEP) meeting on ``AHRQ RFAHS20-002 Supporting Primary Care to Advance Cardiovascular Health in States with High Prevalence of Preventable CVD Events (U18).'' This SEP meeting will be closed to the public. DATES: August 25, 2020. ADDRESSES: Agency for Healthcare Research and Quality, (Video Assisted Review), 5600 Fishers Lane, Rockville, Maryland 20850. FOR FURTHER INFORMATION CONTACT: Jenny Griffith, Committee Management Officer, Office of Extramural Research, Education and Priority Populations, Agency for Healthcare Research and Quality, (AHRQ), 5600 Fishers Lane, Rockville, Maryland 20850, Telephone: (301) 427-1557. SUPPLEMENTARY INFORMATION: A Special Emphasis Panel is a group of experts in fields related to health care research who are invited by AHRQ, and agree to be available, to conduct on an as needed basis, scientific reviews of applications for AHRQ support. Individual members of the Panel do not attend regularly-scheduled meetings and do not serve for fixed terms or a long period of time. Rather, they are asked to participate in particular review meetings which require their type of expertise. The SEP meeting referenced above will be closed to the public in accordance with the provisions set forth in 5 U.S.C. App. 2, section 10(d), 5 U.S.C. 552b(c)(4), and 5 U.S.C. 552b(c)(6). Grant applications for the ``AHRQ RFAHS20-002 Supporting Primary Care to Advance Cardiovascular Health in States with High Prevalence of Preventable CVD Events (U18).'' are to be reviewed and discussed at this meeting. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Agenda items for this meeting are subject to change as priorities dictate. Dated: July 17, 2020. Virginia L. Mackay-Smith, Associate Director. [FR Doc. 2020-15932 Filed 7-22-20; 8:45 am] BILLING CODE 4160-90-P